Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

Sep 29 2018

• By Emily Hayes

FDA approved background, 3D rendering, blue street sign

Related Content

Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

Jul 27 2009

Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology

Dec 13 2017

Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales

May 03 2018

TMB Biomarker Is A Winding Path Rather Than Straight Road

Jun 14 2018

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

AstraZeneca PLC

Roche Holding AG

Pfizer Inc.

Additional Topics

Approvals Business Strategies ImmunoOncology Commercial Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window